Who are Radiotherapy+PCV chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, irinotecan + Carboplatin + erbitux, Flu/Cy/ATG or Cy/ATG, Cytokine-induced killer cells+ FOLFOX4, CEV chemotherapy, HAIC of FOLFOX.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/radiotherapy-pcv-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Radiotherapy+PCV chemotherapy — Competitive Intelligence Brief

Radiotherapy+PCV chemotherapy (Radiotherapy+PCV chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Radiotherapy+PCV chemotherapy (Radiotherapy+PCV chemotherapy) — Assistance Publique - Hôpitaux de Paris. Radiotherapy works by damaging the DNA of cancer cells, while PCV chemotherapy targets rapidly dividing cells with a combination of drugs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Radiotherapy+PCV chemotherapy TARGET	Radiotherapy+PCV chemotherapy	Assistance Publique - Hôpitaux de Paris	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
irinotecan + Carboplatin + erbitux	irinotecan-carboplatin-erbitux	Pfizer	marketed	chemotherapy	topoisomerase I, platinum DNA damage, epidermal growth factor receptor
Flu/Cy/ATG or Cy/ATG	Flu/Cy/ATG or Cy/ATG	Peking University People's Hospital	marketed	Conditioning regimen (combination chemotherapy and immunosuppressive therapy)
Cytokine-induced killer cells+ FOLFOX4	Cytokine-induced killer cells+ FOLFOX4	China Meitan General Hospital	marketed	Cell therapy combined with chemotherapy
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
HAIC of FOLFOX	HAIC of FOLFOX	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (regional delivery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radiotherapy+PCV chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/radiotherapy-pcv-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab